Literature DB >> 29668110

Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells.

Wei Wu1, Deepkamal Karelia1, Kartick Pramanik1, Shantu G Amin1,2, Arun K Sharma1,2, Cheng Jiang1, Junxuan Lu1,2.   

Abstract

Previous studies have established the in vivo bioavailability and efficacious dosages of phenylbutyl isoselenocyanate (ISC-4), a selenium-substituted isothiocyanate, against mouse xenograft models of human melanoma and colorectal cancer. To explore its potential attributes against prostate cancer, we treated human LNCaP prostate cancer cells with ISC-4 and examined their apoptosis responses, and interrogated the signaling mechanisms through pharmacological and siRNA knockdown approaches. Our results show that ISC-4 was more potent at inducing apoptosis than its sulfur analog phenylbutyl isothiocyanate (PBITC) without suppressing protein kinase AKT Ser473 phosphorylation. ISC-4 induced apoptosis in concentration- and time-dependent manners, and the apoptosis execution was attenuated by pre-incubation with a pan caspase inhibitor. ISC-4 decreased the abundance of androgen receptor (AR) and its best known target prostate specific antigen (PSA) without decreasing their steady state mRNA. ISC-4 upregulated the abundance of p53 protein and its Ser15 -phosphorylative activation, and that of DNA double strand break marker Ser139 -p-H2A.X coincident with apoptotic exposure. Similar to the rapid induction of reactive oxygen species (ROS) by isothiocyanates, ISC-4 increased dihydroethidium-detectable signals in LNCaP cells. Pre-incubation with ROS scavenger N-acetyl-l-cysteine preserved AR and PSA abundance, markedly reduced ISC-4-induced apoptosis and attenuated p53 Ser phosphorylation, p21Cip1, and p-H2A.X. Furthermore, siRNA knockdown of p53 did not suppress ROS production, but decreased ISC-4-induced apoptosis. Knocking down p53-targets PUMA and Bax exerted greater protective effect on ISC-4-induced apoptosis than depleting p21Cip1. In summary, ISC-4 inhibited LNCaP cell growth and survival with ROS-mediated suppression of AR axis signaling and induction of p53-PUMA-Bax mitochondrial apoptosis.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  apoptosis; isoselenocyanate; isothiocyanate; p53; prostate cancer

Mesh:

Substances:

Year:  2018        PMID: 29668110     DOI: 10.1002/mc.22825

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  5 in total

1.  Gender Differences in Gastric Cancer Survival: 99,922 Cases Based on the SEER Database.

Authors:  Huafu Li; Zhewei Wei; Chunming Wang; Wei Chen; Yulong He; Changhua Zhang
Journal:  J Gastrointest Surg       Date:  2019-07-25       Impact factor: 3.452

2.  Extracellular Albumin Covalently Sequesters Selenocompounds and Determines Cytotoxicity.

Authors:  Wenyi Zheng; Roberto Boada; Rui He; Tingting Xiao; Fei Ye; Laura Simonelli; Manuel Valiente; Ying Zhao; Moustapha Hassan
Journal:  Int J Mol Sci       Date:  2019-09-24       Impact factor: 5.923

Review 3.  Roles of Reactive Oxygen Species in Biological Behaviors of Prostate Cancer.

Authors:  Chenglin Han; Zilong Wang; Yingkun Xu; Shuxiao Chen; Yuqing Han; Lin Li; Muwen Wang; Xunbo Jin
Journal:  Biomed Res Int       Date:  2020-09-29       Impact factor: 3.411

4.  ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.

Authors:  Hao Tian; Fu-Ju Chou; Jing Tian; Yong Zhang; Bosen You; Chi-Ping Huang; Shuyuan Yeh; Yuanjie Niu; Chawnshang Chang
Journal:  J Exp Clin Cancer Res       Date:  2021-01-04

5.  A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.

Authors:  Joanna L Gillis; Josephine A Hinneh; Natalie K Ryan; Swati Irani; Max Moldovan; Lake-Ee Quek; Raj K Shrestha; Adrienne R Hanson; Jianling Xie; Andrew J Hoy; Jeff Holst; Margaret M Centenera; Ian G Mills; David J Lynn; Luke A Selth; Lisa M Butler
Journal:  Elife       Date:  2021-08-12       Impact factor: 8.140

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.